In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.

Ex Input:
SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Comprehensive Immunosuppressive Drug 
Coverage for Kidney Transplant Patients Act of 2011''.

SEC. 2. EXTENDED MONTHS OF COVERAGE OF IMMUNOSUPPRESSIVE DRUGS FOR 
              KIDNEY TRANSPLANT PATIENTS AND OTHER RENAL DIALYSIS 
              PROVISIONS.

    (a) Medicare Entitlement to Immunosuppressive Drugs for Kidney 
Transplant Recipients.--
            (1) Kidney transplant recipients.--Section 226A(b)(2) of 
        the Social Security Act (42 U.S.C. 426-1(b)(2)) is amended by 
        inserting ``(except for eligibility for enrollment under part B 
        solely for purposes of coverage of immunosuppressive drugs 
        described in section 1861(s)(2)(J))'' before ``, with the 
        thirty-sixth month''.
            (2) Individuals eligible only for coverage of 
        immunosuppressive drugs.--
                    (A) Section 1836 of the Social Security Act (42 
                U.S.C. 1395o) is amended--
                            (i) by striking ``Every'' and inserting 
                        ``(a) In General.--Every''; and
                            (ii) by inserting at the end the following 
                        new subsection:
    ``(b) Individuals Eligible for Immunosuppressive Drug Coverage.--
Beginning on January 1, 2012, every individual whose insurance benefits 
under part A have ended (whether before, on, or after such date) by 
reason of section 226A(b)(2) is eligible for enrollment in the 
insurance program established by this part solely for purposes of 
coverage of immunosuppressive drugs.''.
                    (B) Conforming amendment.--Sections 1837, 1838, and 
                1839 of the Social Security Act (42 U.S.C. 1395(p), 42 
                U.S.C. 1395(q), 42 U.S.C. 1395(r)) are each amended by 
                striking ``1836'' and inserting ``1836(a)'' each place 
                it appears.
            (3) Enrollment for individuals only eligible for coverage 
        of immunosuppressive drugs.--Section 1837 of the Social 
        Security Act (42 U.S.C. 1395(p)) is amended by adding at the 
        end the following new subsection:
    ``(m)(1) Any individual who is eligible under section 1836(b) to 
enroll in the medical insurance program established under this part for 
purposes of coverage of immunosuppressive drugs may enroll only in such 
manner and form as may be prescribed by regulations, and only during an 
enrollment period described in this subsection.
    ``(2) An individual described in paragraph (1) may enroll beginning 
on the first day of the third month before the month in which the 
individual first satisfies section 1836(b).
    ``(3) An individual described in paragraph (1) whose entitlement 
for hospital insurance benefits under part A ends by reason of section 
226A(b)(2) on or after January 1, 2012, shall be deemed to have 
enrolled in the medical insurance program established by this part for 
purposes of coverage of immunosuppressive drugs.''.
            (4) Coverage period for individuals only eligible for 
        coverage of immunosuppressive drugs.--
                    (A) In general.--Section 1838 of the Social 
                Security Act (42 U.S.C. 1395q) is amended by adding at 
                the end the following new subsection:
    ``(g) In the case of an individual described in section 1836(b), 
the following rules shall apply:
            ``(1) In the case of such an individual who is deemed to 
        have enrolled in part B for coverage of immunosuppressive drugs 
        under section 1837(m)(3), such individual's coverage period 
        shall begin on the first day of the month in which the 
        individual first satisfies section 1836(b).
            ``(2) In the case of such an individual who enrolls in part 
        B for coverage of immunosuppressive drugs under section 
        1837(m)(2), such individual's coverage period shall begin on 
        the first day of the month in which the individual first 
        satisfies section 1836(b) or the month following the month in 
        which the individual so enrolls, whichever is later.
            ``(3) The provisions of subsections (b) and (d) shall apply 
        with respect to an individual described in paragraph (1) or 
        (2).
            ``(4) In addition to the reasons for termination under 
        subsection (b), the coverage period of an individual described 
        in paragraph (1) or (2) shall end when the individual becomes 
        entitled to benefits under this title under section 226(a), 
        226(b), or 226A.''.
                    (B) Conforming amendments.--Section 1838(b) of the 
                Social Security Act (42 U.S.C. 1395q(b)) is amended, in 
                the matter following paragraph (2), by adding ``or 
                section 1837(m)(3)'' after ``section 1837(f)'' each 
                place it appears.
            (5) Premiums for individuals only eligible for coverage of 
        immunosuppressive drugs.--Section 1839 of the Social Security 
        Act (42 U.S.C. 1395r) is amended--
                    (A) in subsection (b), by adding at the end the 
                following new sentence: ``No increase in the premium 
                shall be effected for individuals who are enrolled 
                pursuant to section 1836(b) for coverage only of 
                immunosuppressive drugs.''; and
                    (B) by adding at the end the following new 
                subsection:
    ``(j) Determination of Premium for Individuals Only Eligible for 
Coverage of Immunosuppressive Drugs.--The Secretary shall, during 
September of each year, determine and promulgate a monthly premium rate 
for the succeeding calendar year for individuals who enroll only for 
the purpose of coverage of immunosuppressive drugs under section 
1836(b). Such premium shall be equal to 35 percent of the monthly 
actuarial rate for enrollees age 65 and over, determined according to 
paragraph (1), for that succeeding calendar year. The monthly premium 
of each individual enrolled for coverage of immunosuppressive drugs 
under section 1836(b) for each month shall be the amount promulgated in 
this subsection. Such amount shall be adjusted in accordance with 
subsections (c) and (f).''.
            (6) Government contribution.--Section 1844(a) of the Social 
        Security Act (42 U.S.C. 1395w(a)) is amended--
                    (A) in paragraph (3), by striking the period at the 
                end and inserting ``; plus'';
                    (B) by adding at the end the following new 
                paragraph:
            ``(4) a Government contribution equal to the estimated 
        aggregate reduction in premiums payable under part B that 
        results from establishing the premium at 35 percent of the 
        actuarial rate under section 1839(j) instead of 50 percent of 
        the actuarial rate for individuals who enroll only for the 
        purpose of coverage of immunosuppressive drugs under section 
        1836(b).''; and
                    (C) by adding at the end the following flush 
                matter:
        ``The Government contribution under paragraph (4) shall be 
        treated as premiums payable and deposited for purposes of 
        subparagraphs (A) and (B) of paragraph (1).''.
            (7) Extension of secondary payer requirements for esrd 
        beneficiaries eligible for coverage of immunosuppressive 
        drugs.--Section 1862(b)(1)(C) of the Social Security Act (42 
        U.S.C. 1395(y)(b)(1)) is amended by adding at the end the 
        following new sentence: ``With regard to immunosuppressive 
        drugs furnished to an individual who enrolls for the purpose of 
        coverage of immunosuppressive drugs under section 1836(b) on or 
        after January 1, 2012, this subparagraph shall apply without 
        regard to any time limitation, except that when such individual 
        becomes entitled to benefits under this title under sections 
        226(a) or 226(b), or entitled to or eligible for benefits under 
        this title under section 226A, the provisions of subparagraphs 
        (A) and (B), and the time limitations under this subparagraph, 
        respectively, shall apply.''.
            (8) Ensuring coverage under the medicare savings program.--
        Section 1905(p)(1)(A) of the Social Security Act (42 U.S.C. 
        1396d(p)(1)(A)) is amended by inserting ``or an individual who 
        is enrolled under part B for the purpose of coverage of 
        immunosuppressive drugs under section 1836(b)'' after ``section 
        1818''.
            (9) Part d.--Section 1860D-1(a)(3)(A) of the Social 
        Security Act (42 U.S.C. 1395w-101(a)(3)(A)) is amended by 
        inserting ``(but not including an individual enrolled solely 
        for coverage of immunosuppressive drugs under section 
        1836(b))'' before the period at the end.

Ex Output:
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2011 - Amends title II (Old Age, Survivors and Disability Benefits) (OASDI) of the Social Security Act (SSA) to extend the months of coverage of immunosuppressive drugs for kidney transplant patients.

Amends SSA title XVIII (Medicare) to make eligible for enrollment in Medicare part B (Supplementary Medical Insurance), solely for the purpose of such drug coverage, every individual whose insurance benefits under Medicare part A (Hospital Insurance) have ended by reason of a kidney transplant or the end of any requirement for a regular course of dialysis.

Directs the Secretary of Health and Human Services (HHS) to determine a monthly premium rate for such individuals equal to 35% of the monthly actuarial rate for enrollees age 65 and over. Prescribes a formula for detemination of a government contribution to such a premium.


Ex Input:
SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Advancing Research for Neurological 
Diseases Act of 2015''.

SEC. 2. NATIONAL NEUROLOGICAL DISEASES SURVEILLANCE SYSTEM.

    Part P of title III of the Public Health Service Act (42 U.S.C. 
280g et seq.) is amended by adding at the end the following:

``SEC. 399V-6 SURVEILLANCE OF NEUROLOGICAL DISEASES.

    ``(a) In General.--The Secretary, acting through the Director of 
the Centers for Disease Control and Prevention, shall--
            ``(1) enhance and expand infrastructure and activities to 
        track the epidemiology of neurological diseases, including 
        multiple sclerosis and Parkinson's disease; and
            ``(2) incorporate information obtained through such 
        activities into a statistically-sound, scientifically-credible, 
        integrated surveillance system, to be known as the National 
        Neurological Diseases Surveillance System.
    ``(b) Research.--The Secretary shall ensure that the National 
Neurological Diseases Surveillance System is designed in a manner that 
facilitates further research on neurological diseases.
    ``(c) Content.--In carrying out subsection (a), the Secretary--
            ``(1) shall provide for the collection and storage of 
        information on the incidence and prevalence of neurological 
        diseases in the United States;
            ``(2) to the extent practicable, shall provide for the 
        collection and storage of other available information on 
        neurological diseases, such as information concerning--
                    ``(A) demographics and other information associated 
                or possibly associated with neurological diseases, such 
                as age, race, ethnicity, sex, geographic location, and 
                family history;
                    ``(B) risk factors associated or possibly 
                associated with neurological diseases, including 
                genetic and environmental risk factors; and
                    ``(C) diagnosis and progression markers;
            ``(3) may provide for the collection and storage of 
        information relevant to analysis on neurological diseases, such 
        as information concerning--
                    ``(A) the epidemiology of the diseases;
                    ``(B) the natural history of the diseases;
                    ``(C) the prevention of the diseases;
                    ``(D) the detection, management, and treatment 
                approaches for the diseases; and
                    ``(E) the development of outcomes measures; and
            ``(4) may address issues identified during the consultation 
        process under subsection (d).
    ``(d) Consultation.--In carrying out this section, the Secretary 
shall consult with individuals with appropriate expertise, including--
            ``(1) epidemiologists with experience in disease 
        surveillance or registries;
            ``(2) representatives of national voluntary health 
        associations that--
                    ``(A) focus on neurological diseases, including 
                multiple sclerosis and Parkinson's disease; and
                    ``(B) have demonstrated experience in research, 
                care, or patient services;
            ``(3) health information technology experts or other 
        information management specialists;
            ``(4) clinicians with expertise in neurological diseases; 
        and
            ``(5) research scientists with experience conducting 
        translational research or utilizing surveillance systems for 
        scientific research purposes.
    ``(e) Grants.--The Secretary may award grants to, or enter into 
contracts or cooperative agreements with, public or private nonprofit 
entities to carry out activities under this section.
    ``(f) Coordination With Other Federal Agencies.--Subject to 
subsection (h), the Secretary shall make information and analysis in 
the National Neurological Diseases Surveillance System available, as 
appropriate, to Federal departments and agencies, such as the National 
Institutes of Health, the Food and Drug Administration, the Centers for 
Medicare & Medicaid Services, the Agency for Healthcare Research and 
Quality, the Department of Veterans Affairs, and the Department of 
Defense.
    ``(g) Public Access.--Subject to subsection (h), the Secretary 
shall make information and analysis in the National Neurological 
Diseases Surveillance System available, as appropriate, to the public, 
including researchers.
    ``(h) Privacy.--The Secretary shall ensure that privacy and 
security protections applicable to the National Neurological Diseases 
Surveillance System are at least as stringent as the privacy and 
security protections under HIPAA privacy and security law (as defined 
in section 3009(a)(2)).
    ``(i) Report.--Not later than 4 years after the date of the 
enactment of this section, the Secretary shall submit a report to the 
Congress concerning the implementation of this section. Such report 
shall include information on--
            ``(1) the development and maintenance of the National 
        Neurological Diseases Surveillance System;
            ``(2) the type of information collected and stored in the 
        System;
            ``(3) the use and availability of such information, 
        including guidelines for such use; and
            ``(4) the use and coordination of databases that collect or 
        maintain information on neurological diseases.
    ``(j) Definition.--In this section, the term `national voluntary 
health association' means a national nonprofit organization with 
chapters, other affiliated organizations, or networks in States 
throughout the United States.
    ``(k) Authorization of Appropriations.--To carry out this section, 
there is authorized to be appropriated $5,000,000 for each of fiscal 
years 2015 through 2019.''.

Ex Output:
Advancing Research for Neurological Diseases Act of 2015 Amends the Public Health Service Act to require the Centers for Disease Control and Prevention to: (1) enhance and expand infrastructure and activities to track the epidemiology of neurological diseases, including multiple sclerosis and Parkinson's disease; and (2) incorporate information obtained through those activities into a National Neurological Diseases Surveillance System. Requires the Department of Health and Human Services (HHS) to ensure that the System facilitates further research on neurological diseases. Requires HHS to provide for the collection and storage of information on neurological diseases, including the incidence, prevalence, and other information, to the extent practicable.   Requires HHS to: (1) make information and analysis in the System available to federal agencies and to the public, including researchers; and (2) ensure that privacy and security protections applicable to the System are at least as stringent as the protections under the Health Insurance Portability and Accountability Act.


Ex Input:
SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Breast Implant Research and 
Information Act''.

SEC. 2. FINDINGS AND PURPOSE.

    (a) Findings.--Congress makes the following findings:
            (1) According to the Institute of Medicine, it is estimated 
        that 1,000,000 to 2,000,000 American women have received breast 
        implants over the last 35 years. Because there has never been a 
        patient registry for breast implant recipients it is impossible 
        to more accurately determine the number of women who have 
        received breast implants. Yet, the American Society of Plastic 
        Surgeons estimates that in 1999 alone 82,975 women had breast 
        reconstruction following mastectomies and another 167,318 
        American women received breast implants for cosmetic purposes.
            (2) From 1985 until January 2000, FDA received 127,770 
        adverse reaction reports for silicone gel-filled breast 
        implants and 65,720 adverse reaction reports for saline-filled 
        implants.
            (3) Women need complete and accurate information about the 
        potential health risks and advantages of breast implants so 
        that women can make informed decisions.
            (4) Silicone breast implants have never been approved by 
        the Food and Drug Administration; saline breast implants, which 
        consist of a saline solution injected into a silicone envelope, 
        were approved by the agency in 2000 despite alarmingly high 
        complication and reoperation rates. After three years, 43 
        percent of the augmentation patients and 73 percent of the 
        reconstruction patients experienced local complications and 40 
        percent of the reconstruction patients were forced to undergo 
        additional surgery for local complications and device failure.
            (5) In 1998, the Food and Drug Administration opened a 
        criminal investigation following allegations that one of the 
        breast implant manufacturers was manipulating research data in 
        breast implant studies. When the Food and Drug Administration's 
        General and Plastic Surgery Devices Panel convened in March 
        2000 to consider market approval for saline implants, it was 
        not informed of the investigation. Although the manufacturer's 
        saline breast implant was approved by the Food and Drug 
        Administration in May 2000, the investigation remains open.
            (6) According to a 1997 Mayo Clinic study, within 5 years 
        of receiving such implants, 1 in 4 women required additional 
        surgery.
            (7) In 2000, research sponsored by the Food and Drug 
        Administration found that even among women who had not sought 
        medical treatment for implant problems, almost 70 percent had 
        at least one ruptured implant after 10 to 15 years. Silicone 
        was found to be migrating away from the implants in 21 percent 
        of those women. The FDA researchers concluded that ``the 
        relationship of free silicone to development or progression of 
        disease is unknown''.
            (8) A 1993 study by Dr. Suzanne S. Teuber et al., 
        University of California, published in The Journal of 
        Autoimmunity, investigated the influence of silicone breast 
        implants on the expression of anticollagen antibodies and found 
        a statistically significant incidence of anticollagen 
        antibodies in women with implants. The researchers concluded 
        that silicone breast implants should not be considered a benign 
        or immunologically inert material; serious implications may 
        result from their use.
            (9) The Institute of Medicine's 1999 study of silicone 
        breast implant safety found that local complications with 
        silicone breast implants were the primary safety issue, that 
        they have not been well studied, and that information on these 
        complications is crucial for women deciding whether or not they 
        want breast implant surgery. Concern remains that exposure to 
        silicone breast implants may result in currently undefined 
        connective tissue or autoimmune diseases.
            (10) A 2001 National Cancer Institute study found breast 
        implant recipients suffer from higher rates of lung and brain 
        cancer than other plastic surgery patients.
            (11) A 1999 case report by Dr. Suzanne S. Teuber et al., 
        University of California, published in The Journal of 
        Rheumatology, found evidence of silicone migration in women 
        with ruptured or leaking silicone breast implants. These 
        patients experienced severe local inflammation and 
        complications resulting from silicone migration to the axilla, 
        arm or abdominal wall. Researchers concluded that once silicone 
        gel leaves the implant, it is not biologically inert and in 
        some persons can elicit profound pathologic responses.
            (12) According to many reports, including a study published 
        in the Journal of the National Cancer Institute, the presence 
        of a silicone breast implant may create difficulties in 
        obtaining accurate and thorough mammograms because as much as 
        40 percent of the breast tissue can be masked by the implant. 
        This delays the early detection of breast cancer in women.
            (13) According to a 2000 Food and Drug Administration 
        publication, women of childbearing age who want to breast feed 
        should be aware of the negative impact of breast implants on 
        breast feeding. It is not known if a small amount of silicone 
        may pass from the silicone shell of an implant into breast 
        milk. If this occurs, it is not known what effect it may have 
        on the nursing infant.
    (b) Purpose.--It is the purpose of this Act to promote research to 
identify and evaluate the health effects of breast implants, to ensure 
that women receive accurate information about such implants and to 
encourage the Food and Drug Administration to conclude its criminal 
investigation based on the allegations of wrong-doing by one of the 
implant manufacturers which ultimately may affect their products and 
the health of American women.
    (c) Rule of Construction.--Nothing in this Act shall be construed 
to affect any rule or regulation promulgated under the authority of the 
Federal Food, Drug and Cosmetic Act (21 U.S. 301 et seq.) that is in 
effect on the date of enactment of this Act relating to the 
availability of silicone breast implant for reconstruction after 
mastectomy, correction of congenital deformities, or replacement for 
ruptured silicone implants for augmentation.

SEC. 3. EXPANSION AND INTENSIFICATION OF ACTIVITIES REGARDING SILICONE 
              BREAST IMPLANTS AT THE NATIONAL INSTITUTES OF HEALTH.

    (a) Status of Existing Research.--The Director of the National 
Institutes of Health shall report to all appropriate committees of 
Congress on the status of the existing breast implant research funded 
by such Institutes within 90 days after the date of the enactment of 
this Act.
    (b) Amendment to Public Health Service Act.--Part H of title IV of 
the Public Health Service Act (42 U.S.C. 289 et seq.) is amended by 
adding at the end of the following:

``SEC. 498C. BREAST IMPLANT RESEARCH.

    ``(a) Institute-Wide Coordinator.--The Director of NIH shall 
appoint an appropriate official of the Department of Health and Human 
Services to serve as the National Institutes of Health coordinator 
regarding breast implant research. Such coordinator shall encourage and 
coordinate the participation of all appropriate Institutes research 
including--
            ``(1) the Office of Research on Women's Health;
            ``(2) the National Institute of Allergy and Infectious 
        Diseases;
            ``(3) the National Institute of Arthritis and 
        Musculoskeletal and Skin diseases;
            ``(4) the National Institute of Child Health and Human 
        Development;
            ``(5) the National Institute of Environmental Health 
        Sciences;
            ``(6) the National Institute of Neurological Disorders and 
        Stroke; and
            ``(7) the National Cancer Institute.
    ``(b) Study Sections.--The Director of NIH shall establish a study 
section or special emphasis panel if determined to be appropriate, for 
the National Institutes of Health to review extramural research grant 
applications regarding breast implants to ensure the appropriate design 
and high quality of such research and shall take appropriate action to 
ensure the quality of intramural research activities.
    ``(c) Clinical Study.--
            ``(1) In general.--The Director of NIH shall conduct or 
        support research to expand the understanding of the health 
        implications of both saline and silicone breast implants. Such 
        research should, if determined to be scientifically 
        appropriate, include multidisciplinary, clinical, case-
        controlled study of women with breast implants for at least 
        eight years whether it be one prosthesis or multiple, and 
        differentiate between women receiving implants for mastectomy, 
reconstructive or cosmetic purposes and include subsets of women with 
saline implants and silicone implants. Such a study should focus on the 
rate of local complications which includes capsular contracture, 
leakage, loss of nipple sensation, deflation and rupture as well the 
presentation of atypical symptoms, silicone migration, neurological 
dysfunction, and immune system irregularities, and evaluate to what 
extent if any, their health differs from that of suitable controls.
            ``(2) Annual report.--The Director of NIH shall annually 
        prepare and submit to the appropriate Committees of Congress a 
        report concerning the results of the study conducted under 
        paragraph (1).''.

SEC. 4. INTENSIFICATION OF ACTIVITIES REGARDING POSTMARKET RESEARCH OF 
              SALINE BREAST IMPLANTS AT THE FOOD AND DRUG 
              ADMINISTRATION.

    To ensure that the Food and Drug Administration conducts postmarket 
evaluations of saline implant manufacturers' data based on the 
postmarket recommendations made by the Food and Drug Administration's 
General and Plastic Surgery Devices Panel, the Commissioner of Food and 
Drugs shall report to Congress on the implementation status of the 
postmarket recommendations at 6, 12, and 18 month intervals after the 
date of the enactment of this Act and annually thereafter.

SEC. 5. EXPANSION AND INTENSIFICATION OF ACTIVITIES REGARDING SILICONE 
              BREAST IMPLANTS AT THE FOOD AND DRUG ADMINISTRATION.

    To assist women in receiving accurate and complete information 
about the risks of silicone breast implants, the Commissioner of Food 
and Drugs shall--
            (1) expedite the conclusion the agency's criminal 
        investigation into allegations of wrong-doing by one of the 
        implant manufacturers; brief appropriate Committees of Congress 
        on the findings and take appropriate action within 90 days 
        after the date of the enactment of this Act;
            (2) ensure that the toll-free consumer information line and 
        materials concerning breast implants provided by the Food and 
        Drug Administration are available, up to date, and responsive 
        to reports of problems with breast implants, and that timely 
        aggregate data concerning such reports shall be made available 
        to the public upon request and consistent with existing 
        confidentiality standards;
            (3) require that manufacturers of silicone breast implants 
        update implant package inserts and informed consent documents 
        regularly to reflect accurate information about such implants, 
        particularly the rate of local complications and ruptures of 
        such implants;
            (4) require that any manufacturers of such implants that 
        are conducting clinical studies on silicone breast implants--
                    (A) require its clinical investigators to provide 
                prospective patients with the Food and Drug 
                Administration's breast implant booklet;
                    (B) amend such study protocol and informed consent 
                document to reflect that patients must be provided with 
                a copy of informed consent documents at the initial, or 
                earliest possible, consultation regarding breast 
                prosthesis;
                    (C) amend the informed consent protocol to inform 
                women about how to obtain a Medwatch form and encourage 
                any woman who withdraws from the study, or who would 
                like to report such problem or concerns with the study 
                and reason for withdrawing; and
                    (D) amend the informed consent document to provide 
                potential participants with the inclusion criteria for 
                the clinical trial and the toll-free Consumer 
                Information number; and
            (5) appoint a special ad hoc patient information panel 
        that--
                    (A) convenes annually for the sole purpose of 
                reviewing breast implant information and advertisements 
                provided by the manufacturers and the Food and Drug 
                Administration to ensure consumer information is 
                thorough and accurate; and
                    (B) includes in its membership (but is not limited 
                to) saline and silicone breast implant recipients, 
                bioethicists, rheumatologists, and oncologists with 
                experience in both clinical care and research regarding 
                breast implants.

Ex Output:

Breast Implant Research and Information Act - Requires the Director of the National Institutes of Health (NIH) to report to all appropriate committees of Congress on the status of the existing breast implant research funded by such Institutes.Amends the Public Health Service Act to require the NIH Director to: (1) appoint an official of the Department of Health and Human Services to serve as the NIH coordinator regarding breast implant research; (2) establish either a study section or special emphasis panel for NIH to review extramural breast implant research grant applications to ensure research design and quality, as well as quality intramural research; and (3) conduct or support research to expand the understanding of the health implications of both saline and silicone breast implants.Requires a report from the Commissioner of Food and Drugs concerning postmarket evaluations of saline implant manufacturers' data.Directs the Commissioner to take specified steps to assist women in receiving accurate and complete information about the risks of silicone breast implants.